Prostate Cancer Articles

Frontline Advances Continue in Castration-Sensitive Prostate Cancer
James Luke Godwin, MD, recaps recent advancements in frontline metastatic castration-sensitive prostate cancer and highlights emerging agents with potential in this space.
FDA Grants Enzalutamide Priority Review for Nonmetastatic CRPC
The FDA has granted a priority review to a supplemental new drug application (sNDA) for enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.
Expert Makes Case for Hypofractionation in Prostate Cancer
Howard M. Sandler, MD, discusses the emergence of hypofractionation as a viable treatment approach for patients with prostate cancer.
Expert Emphasizes Healthy Lifestyle in Prostate Cancer Care
Stephen J. Freedland, MD, shares his insight on how to counsel patients with prostate cancer on the benefits of leading a healthier life.
Expert Discusses Optimizing HIFU and Other Strategies in Prostate Cancer
Timothy J. Daskivich, MD, discusses the use of High-intensity focused ultrasound and other treatment strategies in the prostate cancer armamentarium.
Apalutamide Added to NCCN Prostate Cancer Guidelines
The NCCN now lists apalutamide (Erleada) as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate cancer. 
2018 Ushers in New Era of Prostate Cancer Treatment
Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.
Apalutamide Approval Paves Way for Further Advances in Nonmetastatic CRPC
Alan H. Bryce, MD, discusses emerging agents and next steps in the treatment of patients with in nonmetastatic prostate cancer.
Surgery, Brachytherapy-based Radiotherapy Induce Similar Survival in Localized Prostate Cancer
Investigators found no statistically significant difference in survival between radical prostatectomy alone and external beam radiotherapy plus brachytherapy with or without ADT after adjusting for imbalances in prostate cancer prognostic factors.
Risk Stratification Critical to Optimal Prostate Cancer Care
Erik P. Castle, MD, discusses the importance of risk stratifying low- and intermediate-risk localized prostate cancers.
Publication Bottom Border
Border Publication